Ticker brief
SYRE
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
14
authors 14d
10
crowd 14d
-1.6σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-13 · now -0.65 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 4 | -0.26 |
| @bioinvestor24 | A | -0.87 | 2 | +0.70 |
| @BioStocks | C | -1.77 | 1 | -0.35 |
| @AlertsAndNews | C | -3.92 | 1 | -0.25 |
| @Briefingcom | B | -2.26 | 1 | -0.25 |
| @OpenOutcrier | C | · | 1 | -0.35 |
| @Tickeron | C | +1.53 | 1 | -0.65 |
| @UTEX_io | C | +0.04 | 1 | -0.50 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
| @Biotech2k1 | A | +1.11 | 1 | -0.65 |
Recent signals14of 14 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-13 | @Biotech2k1 | -0.65 | Labels the named biotech stocks as bubble names and excludes them from bargains. | · | tweet ↗ |
| 2026-10-12 | @Quantumup1 | +0.40 | UBS initiated SYRE at Buy with a $120 target based on its IBD combination portfolio. | · | tweet ↗ |
| 2026-10-10 | @BiopharmIQ | +0.25 | Ranks biotech names by hedge-fund mentions in the platform's Q3 dataset. | · | tweet ↗ |
| 2026-10-06 | @bioinvestor24 | +0.65 | Calls indiscriminate biotech selling a buying opportunity and favors SYRE's pipeline. | · | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | -0.40 | Reports sharp opening declines tied to a Phase 3 update, interim data and an equity raise. | · | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | -0.50 | SYRE falls after a $350 million offering despite positive prior data and substantial cash runway. | · | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | -0.40 | Biotech mover list quantifies the largest negative opening reactions and their associated catalysts. | · | tweet ↗ |
| 2026-10-06 | @UTEX_io | -0.50 | Reports a $350 million public offering that dilutes existing shareholders. | · | tweet ↗ |
| 2026-10-06 | @Tickeron | -0.65 | Reports a discounted $350M public offering causing dilution and a 9.4% decline. | · | tweet ↗ |
| 2026-10-06 | @OpenOutcrier | -0.35 | Reports Spyre pricing a $350M stock offering at $85 per share. | · | tweet ↗ |
| 2026-10-06 | @Briefingcom | -0.25 | Spyre priced a 4.12 million-share public offering at $85 for about $350 million. | · | tweet ↗ |
| 2026-10-05 | @AlertsAndNews | -0.25 | Spyre priced a $350M underwritten public offering of 4.12M shares at $85 each. | · | tweet ↗ |
| 2026-10-05 | @bioinvestor24 | +0.75 | Praises SYRE's autoimmune trial plan and compares its value with MRK's acquisition spending. | · | tweet ↗ |
| 2026-10-05 | @BioStocks | -0.35 | Reports SYRE pricing a $350 million offering at $85 per share. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.